Download PDF
Semin Plast Surg 2021; 35(03): 159-163
DOI: 10.1055/s-0041-1731462
Review Article

When Benign Becomes Cancer: Malignant Degeneration of Chronic Inflammation

Christopher Conlon
1   Division of Plastic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas
,
Lauren Pupa
2   School of Medicine, Baylor College of Medicine, Houston, Texas
,
Edward M. Reece
1   Division of Plastic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas
3   Division of Plastic Surgery, Texas Children's Hospital, Houston, Texas
,
Carrie K. Chu
4   Department of Plastic Surgery, MD Anderson Cancer Center, University of Texas, Houston, Texas
,
Jessie Z. Yu
1   Division of Plastic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas
,
Joshua Vorstenbosch
5   Division of Plastic Surgery, McGill University, Montreal, Canada
,
Sebastian Winocour
1   Division of Plastic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Chronic inflammation, long implicated in the genesis of malignancy, is now understood to underlie an estimated 25% of all cancers. The most pertinent malignancies, to the plastic surgeon, associated with the degeneration of chronic inflammation include Marjolin's ulcer, breast implant-associated large cell lymphoma, radiation-induced sarcoma, and Kaposi's sarcoma. The cellular and genetic damage incurred by a prolonged inflammatory reaction is controlled by an increasingly understood cytokinetic system. Advances in understanding the chronic inflammatory cascade have yielded new therapeutics and therapeutic targets.

Keywords

chronic inflammation - malignant degeneration - Marjolin's ulcer - BI-ALCL - radiation-induced sarcoma - Kaposi's sarcoma


Publication History

Article published online:
06 July 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001; 357 (9255): 539-545
    CrossrefPubMedGoogle Scholar
  • 2 Korniluk A, Koper O, Kemona H, Dymicka-Piekarska V. From inflammation to cancer. Ir J Med Sci 2017; 186 (01) 57-62
    CrossrefPubMedGoogle Scholar
  • 3 Ikwegbue PC, Masamba P, Mbatha LS, Oyinloye BE, Kappo AP. Interplay between heat shock proteins, inflammation and cancer: a potential cancer therapeutic target. Am J Cancer Res 2019; 9 (02) 242-249
    PubMedGoogle Scholar
  • 4 Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 2017; 14 (07) 399-416
    CrossrefPubMedGoogle Scholar
  • 5 Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013; 14 (10) 1014-1022
    CrossrefPubMedGoogle Scholar
  • 6 Brocker C, Thompson D, Matsumoto A, Nebert DW, Vasiliou V. Evolutionary divergence and functions of the human interleukin (IL) gene family. Hum Genomics 2010; 5 (01) 30-55
    CrossrefPubMedGoogle Scholar
  • 7 Bazaliński D, Przybek-Mita J, Barańska B, Więch P. Marjolin's ulcer in chronic wounds - review of available literature. Contemp Oncol (Pozn) 2017; 21 (03) 197-202
    PubMedGoogle Scholar
  • 8 Pekarek B, Buck S, Osher L. A comprehensive review on Marjolin's ulcers: diagnosis and treatment. J Am Col Certif Wound Spec 2011; 3 (03) 60-64
    PubMedGoogle Scholar
  • 9 Kerr-Valentic MA, Samimi K, Rohlen BH, Agarwal JP, Rockwell WB. Marjolin's ulcer: modern analysis of an ancient problem. Plast Reconstr Surg 2009; 123 (01) 184-191
    CrossrefPubMedGoogle Scholar
  • 10 Fleming MD, Hunt JL, Purdue GF, Sandstad J. Marjolin's ulcer: a review and reevaluation of a difficult problem. J Burn Care Rehabil 1990; 11 (05) 460-469
    CrossrefPubMedGoogle Scholar
  • 11 Copcu E. Marjolin's ulcer: a preventable complication of burns?. Plast Reconstr Surg 2009; 124 (01) 156e-164e
    CrossrefPubMedGoogle Scholar
  • 12 Saaiq M, Ashraf B. Marjolin's ulcers in the post-burned lesions and scars. World J Clin Cases 2014; 2 (10) 507-514
    CrossrefPubMedGoogle Scholar
  • 13 Asuquo M, Ugare G, Ebughe G, Jibril P. Marjolin's ulcer: the importance of surgical management of chronic cutaneous ulcers. Int J Dermatol 2007; 46 (Suppl. 02) 29-32
    CrossrefPubMedGoogle Scholar
  • 14 Gan BS, Colcleugh RG, Scilley CG, Craig ID. Melanoma arising in a chronic (Marjolin's) ulcer. J Am Acad Dermatol 1995; 32 (06) 1058-1059
    CrossrefPubMedGoogle Scholar
  • 15 Smith J, Mello LFB, Nogueira Neto NC. et al. Malignancy in chronic ulcers and scars of the leg (Marjolin's ulcer): a study of 21 patients. Skeletal Radiol 2001; 30 (06) 331-337
    CrossrefPubMedGoogle Scholar
  • 16 Copcu E, Aktas A, Sişman N, Oztan Y. Thirty-one cases of Marjolin's ulcer. Clin Exp Dermatol 2003; 28 (02) 138-141
    CrossrefPubMedGoogle Scholar
  • 17 Kowal-Vern A, Criswell BK. Burn scar neoplasms: a literature review and statistical analysis. Burns 2005; 31 (04) 403-413
    CrossrefPubMedGoogle Scholar
  • 18 Beachkofsky TM, Wisco OJ, Owens NM, Hodson DS. Verrucous nodules on the ankle. J Fam Pract 2009; 58 (08) 427-430
    PubMedGoogle Scholar
  • 19 Møller R, Reymann F, Hou-Jensen K. Metastases in dermatological patients with squamous cell carcinoma. Arch Dermatol 1979; 115 (06) 703-705
    CrossrefPubMedGoogle Scholar
  • 20 Choi JY, Bae YC, Nam SB, Bae SH. Impact of disturbed wound healing after surgery on the prognosis of Marjolin's ulcer. Arch Plast Surg 2013; 40 (03) 198-202
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Chalya PL, Mabula JB, Rambau P. et al. Marjolin's ulcers at a university teaching hospital in Northwestern Tanzania: a retrospective review of 56 cases. World J Surg Oncol 2012; 10: 38
    CrossrefPubMedGoogle Scholar
  • 22 Oruç M, Kankaya Y, Sungur N. et al. Clinicopathological evaluation of Marjolin ulcers over two decades. Kaohsiung J Med Sci 2017; 33 (07) 327-333
    CrossrefPubMedGoogle Scholar
  • 23 Kirsner RS, Spencer J, Falanga V, Garland LE, Kerdel FA. Squamous cell carcinoma arising in osteomyelitis and chronic wounds. Treatment with Mohs micrographic surgery vs amputation. Dermatol Surg 1996; 22 (12) 1015-1018
    CrossrefPubMedGoogle Scholar
  • 24 Aydoğdu E, Yildirim S, Aköz T. Is surgery an effective and adequate treatment in advanced Marjolin's ulcer?. Burns 2005; 31 (04) 421-431
    CrossrefPubMedGoogle Scholar
  • 25 Keech Jr JA, Creech BJ. Anaplastic T-cell lymphoma in proximity to a saline-filled breast implant. Plast Reconstr Surg 1997; 100 (02) 554-555
    CrossrefPubMedGoogle Scholar
  • 26 Swerdlow SH, Campo E, Pileri SA. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127 (20) 2375-2390
    CrossrefPubMedGoogle Scholar
  • 27 Food and Drug Administration. Medical Device Reports of Breast Implant-Associated Anaplastic Large Cell Lymphoma. Rockville, MD: August 20, 2020. Medical Device Reports
    PubMedGoogle Scholar
  • 28 Miranda RN, Aladily TN, Prince HM. et al. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol 2014; 32 (02) 114-120
    CrossrefPubMedGoogle Scholar
  • 29 Doren EL, Miranda RN, Selber JC. et al. U.S. epidemiology of breast implant-associated anaplastic large cell lymphoma. Plast Reconstr Surg 2017; 139 (05) 1042-1050
    CrossrefPubMedGoogle Scholar
  • 30 de Boer M, van Leeuwen FE, Hauptmann M. et al. Breast implants and the risk of anaplastic large-cell lymphoma in the breast. JAMA Oncol 2018; 4 (03) 335-341
    CrossrefPubMedGoogle Scholar
  • 31 Ferrufino-Schmidt MC, Medeiros LJ, Liu H. et al. Clinicopathologic features and prognostic impact of lymph node involvement in patients with breast implant-associated anaplastic large cell lymphoma. Am J Surg Pathol 2018; 42 (03) 293-305
    CrossrefPubMedGoogle Scholar
  • 32 Magnusson M, Beath K, Cooter R. et al. The epidemiology of breast implant-associated anaplastic large cell lymphoma in Australia and New Zealand confirms the highest risk for grade 4 surface breast implants. Plast Reconstr Surg 2019; 143 (05) 1285-1292
    CrossrefPubMedGoogle Scholar
  • 33 Clemens MW, Medeiros LJ, Butler CE. et al. Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. J Clin Oncol 2016; 34 (02) 160-168
    CrossrefPubMedGoogle Scholar
  • 34 Clemens MW, Brody GS, Mahabir RC, Miranda RN. How to diagnose and treat breast implant-associated anaplastic large cell lymphoma. Plast Reconstr Surg 2018; 141 (04) 586e-599e
    CrossrefPubMedGoogle Scholar
  • 35 McCarthy CMM, Loyo-Berríos N, Qureshi AA. et al. Patient registry and outcomes for breast implants and anaplastic large cell lymphoma etiology and epidemiology (PROFILE): initial report of findings, 2012-2018. Plast Reconstr Surg 2019; 143 (3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma): 65S-73S
    CrossrefPubMedGoogle Scholar
  • 36 Clemens MW, Jacobsen ED, Horwitz SM. 2019 NCCN consensus guidelines on the diagnosis and treatment of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Aesthet Surg J 2019; 39 (Suppl. 01) S3-S13
    CrossrefPubMedGoogle Scholar
  • 37 Miller KD, Siegel RL, Lin CC. et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016; 66 (04) 271-289
    CrossrefPubMedGoogle Scholar
  • 38 Beck A. Zur frage des Rontgensarkoms, Zugleich ein Beitrag zur pathogenese des sarkoms. Munch Med Wochenschr 1922; 69: 623-624
    PubMedGoogle Scholar
  • 39 Burtt JJ, Thompson PA, Lafrenie RM. Non-targeted effects and radiation-induced carcinogenesis: a review. J Radiol Prot 2016; 36 (01) R23-R35
    CrossrefPubMedGoogle Scholar
  • 40 Kirova YM, Vilcoq JR, Asselain B, Sastre-Garau X, Fourquet A. Radiation-induced sarcomas after radiotherapy for breast carcinoma: a large-scale single-institution review. Cancer 2005; 104 (04) 856-863
    CrossrefPubMedGoogle Scholar
  • 41 Thiagarajan A, Iyer NG. Radiation-induced sarcomas of the head and neck. World J Clin Oncol 2014; 5 (05) 973-981
    CrossrefPubMedGoogle Scholar
  • 42 Sheth GR, Cranmer LD, Smith BD, Grasso-Lebeau L, Lang JE. Radiation-induced sarcoma of the breast: a systematic review. Oncologist 2012; 17 (03) 405-418
    CrossrefPubMedGoogle Scholar
  • 43 Olcina M, Merck B, Giménez-Climent MJ. et al. Radiation-induced leiomyosarcoma after breast cancer treatment and TRAM flap reconstruction. Sarcoma 2008; 2008: 456950
    CrossrefPubMedGoogle Scholar
  • 44 Chahin F, Paramesh A, Dwivedi A. et al. Angiosarcoma of the breast following breast preservation therapy and local radiation therapy for breast cancer. Breast J 2001; 7 (02) 120-123
    CrossrefPubMedGoogle Scholar
  • 45 Rubino C, Shamsaldin A, Lê MG. et al. Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment. Breast Cancer Res Treat 2005; 89 (03) 277-288
    CrossrefPubMedGoogle Scholar
  • 46 Karlsson P, Holmberg E, Samuelsson A, Johansson KA, Wallgren A. Soft tissue sarcoma after treatment for breast cancer--a Swedish population-based study. Eur J Cancer 1998; 34 (13) 2068-2075
    CrossrefPubMedGoogle Scholar
  • 47 Samartzis D, Nishi N, Cologne J. et al. Ionizing radiation exposure and the development of soft-tissue sarcomas in atomic-bomb survivors. J Bone Joint Surg Am 2013; 95 (03) 222-229
    CrossrefPubMedGoogle Scholar
  • 48 De Smet S, Vandermeeren L, Christiaens M-R. et al. Radiation-induced sarcoma: analysis of 46 cases. Acta Chir Belg 2008; 108 (05) 574-579
    CrossrefPubMedGoogle Scholar
  • 49 Cahan WG, Woodard HQ, Higinbotham NL, Stewart FW, Coley BL. Sarcoma arising in irradiated bone: report of eleven cases. 1948. Cancer 1998; 82 (01) 8-34
    CrossrefPubMedGoogle Scholar
  • 50 Callesen LB, Safwat A, Rose HK, Sørensen FB, Baad-Hansen T, Aggerholm-Pedersen N. Radiation-induced sarcoma: a retrospective population-based study over 34 years in a single institution. Clin Oncol (R Coll Radiol) 2021; 33 (05) e232-e238
    CrossrefPubMedGoogle Scholar
  • 51 Thijssens KMJ, van Ginkel RJ, Suurmeijer AJH. et al. Radiation-induced sarcoma: a challenge for the surgeon. Ann Surg Oncol 2005; 12 (03) 237-245
    CrossrefPubMedGoogle Scholar
  • 52 Erel E, Vlachou E, Athanasiadou M, Hassan S, Chandrasekar CR, Peart F. Management of radiation-induced sarcomas in a tertiary referral centre: a review of 25 cases. Breast 2010; 19 (05) 424-427
    CrossrefPubMedGoogle Scholar
  • 53 Yap J, Chuba PJ, Thomas R. et al. Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys 2002; 52 (05) 1231-1237
    CrossrefPubMedGoogle Scholar
  • 54 Neuhaus SJ, Pinnock N, Giblin V. et al. Treatment and outcome of radiation-induced soft-tissue sarcomas at a specialist institution. Eur J Surg Oncol 2009; 35 (06) 654-659
    CrossrefPubMedGoogle Scholar
  • 55 Blanchard DK, Reynolds C, Grant CS, Farley DR, Donohue JH. Radiation-induced breast sarcoma. Am J Surg 2002; 184 (04) 356-358
    CrossrefPubMedGoogle Scholar
  • 56 Kaposi M. Idiopathisches multiples Pigmentsarkom der Haut. Arch Dermatol Syph 1872; 4 (02) 265-273
    CrossrefPubMedGoogle Scholar
  • 57 Luo Q, Satcher Johnson A, Hall HI, Cahoon EK, Shiels M. Kaposi sarcoma rates among persons living with human immunodeficiency virus in the United States: 2008-2016. Clin Infect Dis 2020; •••: ciaa999
    CrossrefPubMedGoogle Scholar
  • 58 Grulich AE, Vajdic CM. The epidemiology of cancers in human immunodeficiency virus infection and after organ transplantation. Semin Oncol 2015; 42 (02) 247-257
    CrossrefPubMedGoogle Scholar
  • 59 Radu O, Pantanowitz L. Kaposi sarcoma. Arch Pathol Lab Med 2013; 137 (02) 289-294
    CrossrefPubMedGoogle Scholar
  • 60 Cesarman E, Damania B, Krown SE, Martin J, Bower M, Whitby D. Kaposi sarcoma. Nat Rev Dis Primers 2019; 5 (01) 9
    CrossrefPubMedGoogle Scholar
  • 61 Orenstein JM. Ultrastructure of Kaposi sarcoma. Ultrastruct Pathol 2008; 32 (05) 211-220
    CrossrefPubMedGoogle Scholar
  • 62 Northfelt DW, Dezube BJ, Thommes JA. et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998; 16 (07) 2445-2451
    CrossrefPubMedGoogle Scholar
  • 63 Stewart S, Jablonowski H, Goebel FD. et al; International Pegylated Liposomal Doxorubicin Study Group. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol 1998; 16 (02) 683-691
    CrossrefPubMedGoogle Scholar
  • 64 Cianfrocca M, Lee S, Von Roenn J. et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer 2010; 116 (16) 3969-3977
    CrossrefPubMedGoogle Scholar
  • 65 Chen I-Y, Ichinohe T. Response of host inflammasomes to viral infection. Trends Microbiol 2015; 23 (01) 55-63
    CrossrefPubMedGoogle Scholar
  • 66 Harland DL, Robinson WA, Franklin WA. Deletion of the p53 gene in a patient with aggressive burn scar carcinoma. J Trauma 1997; 42 (01) 104-107
    CrossrefPubMedGoogle Scholar
  • 67 Lee SH, Shin MS, Kim HS. et al. Somatic mutations of Fas (Apo-1/CD95) gene in cutaneous squamous cell carcinoma arising from a burn scar. J Invest Dermatol 2000; 114 (01) 122-126
    CrossrefPubMedGoogle Scholar
  • 68 Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. The origin and function of tumor-associated macrophages. Immunol Today 1992; 13 (07) 265-270
    CrossrefPubMedGoogle Scholar
  • 69 Treves N, Pack G. The development of cancer in burn scars. Surg Gynecol Obstet 1930; 51: 749-782
    PubMedGoogle Scholar
  • 70 Novick M, Gard DA, Hardy SB, Spira M. Burn scar carcinoma: a review and analysis of 46 cases. J Trauma 1977; 17 (10) 809-817
    CrossrefPubMedGoogle Scholar
  • 71 Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Rüttinger D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer 2017; 5 (01) 53
    CrossrefPubMedGoogle Scholar
  • 72 Allavena P, Sica A, Vecchi A, Locati M, Sozzani S, Mantovani A. The chemokine receptor switch paradigm and dendritic cell migration: its significance in tumor tissues. Immunol Rev 2000; 177: 141-149
    CrossrefPubMedGoogle Scholar
  • 73 van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. Am J Pathol 1999; 154 (06) 1685-1691
    CrossrefPubMedGoogle Scholar
  • 74 Brunet JF, Denizot F, Luciani MF. et al. A new member of the immunoglobulin superfamily--CTLA-4. Nature 1987; 328 (6127): 267-270
    CrossrefPubMedGoogle Scholar
  • 75 Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704
    CrossrefPubMedGoogle Scholar
  • 76 Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480 (7378): 480-489
    CrossrefPubMedGoogle Scholar
  • 77 Seyfizadeh N, Seyfizadeh N, Gharibi T, Babaloo Z. Interleukin-13 as an important cytokine: a review on its roles in some human diseases. Acta Microbiol Immunol Hung 2015; 62 (04) 341-378
    CrossrefPubMedGoogle Scholar
  • 78 Kadin ME, Morgan J, Xu H. et al. IL-13 is produced by tumor cells in breast implant-associated anaplastic large cell lymphoma: implications for pathogenesis. Hum Pathol 2018; 78: 54-62
    CrossrefPubMedGoogle Scholar
  • 79 Ingram JL, Kraft M. IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies. J Allergy Clin Immunol 2012; 130 (04) 829-842 , quiz 843–844
    CrossrefPubMedGoogle Scholar
  • 80 Vatrella A, Fabozzi I, Calabrese C, Maselli R, Pelaia G. Dupilumab: a novel treatment for asthma. J Asthma Allergy 2014; 7: 123-130
    CrossrefPubMedGoogle Scholar
  • 81 Lechner MG, Megiel C, Church CH. et al. Survival signals and targets for therapy in breast implant-associated ALK--anaplastic large cell lymphoma. Clin Cancer Res 2012; 18 (17) 4549-4559
    CrossrefPubMedGoogle Scholar
  • 82 Monini P, Colombini S, Stürzl M. et al. Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma. Blood 1999; 93 (12) 4044-4058
    PubMedGoogle Scholar
  • 83 Schulz TF, Cesarman E. Kaposi sarcoma-associated herpesvirus: mechanisms of oncogenesis. Curr Opin Virol 2015; 14: 116-128
    CrossrefPubMedGoogle Scholar
  • 84 Fedeles BI, Freudenthal BD, Yau E. et al. Intrinsic mutagenic properties of 5-chlorocytosine: a mechanistic connection between chronic inflammation and cancer. Proc Natl Acad Sci U S A 2015; 112 (33) E4571-E4580
    CrossrefPubMedGoogle Scholar
  • 85 de Bree E, van Coevorden F, Peterse JL, Russell NS, Rutgers EJ. Bilateral angiosarcoma of the breast after conservative treatment of bilateral invasive carcinoma: genetic predisposition?. Eur J Surg Oncol 2002; 28 (04) 392-395
    CrossrefPubMedGoogle Scholar